CA3024230C — Lyophilized preparation of cytotoxic dipeptides
Assigned to Oncopeptides Innovation AB · Expires 2022-10-18 · 4y expired
What this patent protects
The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; .beta.-cyclodextrin; ocyclodext…
USPTO Abstract
The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; .beta.-cyclodextrin; ocyclodextrin; hydroxypropyl-.beta.-cyclodextrin; sulfobutylether-.beta.-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.
Drugs covered by this patent
- Vocabria (CABOTEGRAVIR) · GSK
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.